GlassScriptPhysician profile
Roya Nayeri
NPI 1225606460
$14,656.18
in general payments reported to CMS, 2019-2025
26 companies · $5,916 in 2025
The $5,916 reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $68.33 · 2022: $1,884 · 2023: $2,271 · 2024: $4,517 · 2025: $5,916.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Consulting Fee: $2,035 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,656.81 |
| Consulting Fee | $2,035.00 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,628.33 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $2,611.38 | 2024-2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $1,212.71 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $1,153.73 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $986.33 | 2022-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $933.83 | 2022-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $899.60 | 2021-2025 | Lybalvi, Aristada, Vivitrol |
| Neurocrine Biosciences, INC. | $845.13 | 2023-2025 | Ingrezza |
| Corium, LLC | $772.79 | 2022-2025 | Azstarys |
| Axsome Therapeutics, INC. | $549.99 | 2023-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $463.33 | 2022-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Lundbeck LLC | $379.83 | 2022-2025 | Rexulti |
| Ironshore Pharmaceuticals INC. | $240.14 | 2021-2024 | Jornay Pm |
| Indivior INC. | $208.84 | 2024-2025 | Sublocade |
| Almatica Pharma LLC | $149.44 | 2021-2025 | Loreev Xr, Sertraline Hcl |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $147.58 | 2022 | |
| Supernus Pharmaceuticals, INC. | $140.90 | 2023 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $118.55 | 2022-2023 | Trintellix |
| Noven Therapeutics, LLC | $68.17 | 2024-2025 | Xelstrym, Secuado |
| Idorsia Pharmaceuticals US INC | $30.29 | 2023 | Quviviq |
| Tris Pharma INC | $27.71 | 2022-2023 | Dyanavel Xr |
| Bausch Health US, LLC | $19.95 | 2025 | Aplenzin |
| Alfasigma USA, INC. | $18.49 | 2022 | |
| Harmony Biosciences LLC | $17.64 | 2024 | |
| Merck Sharp & Dohme LLC | $17.39 | 2023 | Belsomra |
| Neos Therapeutics, LP | $14.11 | 2023 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roya Nayeri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.